

Special Issue

Drug-Induced Diseases in the Elderly

Message from the Guest Editors

It is common knowledge that medicines may induce or worsen several diseases. In some cases, drug-induced diseases are characterized by clinical and/or laboratory distinctive findings that are different from those of the correspondent "primary" diseases. In the elderly patients, polypharmacology has specific effects, often absent in other age groups, so that the role of over-the-counter products is by no means secondary. Moreover, age-related changes are possible both in pharmacodynamics and in pharmacokinetics. The purpose of this Special Issue of *Medicines* is to explore all aspects of the wide world of drug-induced diseases in the elderly. We invite all colleagues to submit their research or review manuscripts on this important topic.

Guest Editors

Dr. Alberto Castagna


Primary Care Department, Center for Cognitive Disorders and Dementia DSS Catanzaro Azienda Sanitaria Provinciale di Catanzaro, Viale Crotona 88100 Catanzaro, Italy

Dr. Ciro Manzo

Azienda Sanitaria Locale Napoli 3 sud. Chief pf Rheumatologic outpatient clinic, health district no. 59 - 80065, Sant'Agnello, Naples, Italy

Deadline for manuscript submissions

closed (31 May 2021)



Medicines

an Open Access Journal
by MDPI

Indexed in PubMed




mdpi.com/si/67725

Medicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
medicines@mdpi.com

[mdpi.com/journal/
medicines](https://mdpi.com/journal/medicines)





Medicines

an Open Access Journal
by MDPI

Indexed in PubMed



[mdpi.com/journal/
medicines](https://mdpi.com/journal/medicines)



About the Journal

Message from the Editor-in-Chief

Medicines (ISSN 2305-6320) is an international, peer-reviewed, and open-access journal aimed at disseminating cutting-edge research in the field of drug discovery and clinical application. It publishes original research papers, research communications, letters, and systematic reviews. The contents of the papers handled are manufacture of new drugs, exploration of drug-delivery systems, therapeutic effect, action mechanism, and their modulation by intrinsic and extrinsic factors. We look forward to handling your contributions in the very near future.

Editor-in-Chief

Prof. Dr. Hiroshi Sakagami

Meikai University Research Institute of Odontology (M-RIO), 1-1
Keyakidai, Sakado, Saitama 350-0283, Japan

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within PubMed, PMC, CAPlus / SciFinder, and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 45 days after submission; acceptance to publication is undertaken in 5.7 days (median values for papers published in this journal in the first half of 2025).